These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12587428)

  • 1. [The role of membrane glycoproteins CD46, CD55 and CD59 in protection of tumor cells against complement lysis].
    Wojnicz D; Bar J; Jankowski S
    Postepy Hig Med Dosw; 2002; 56(5):603-16. PubMed ID: 12587428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
    Gorter A; Blok VT; Haasnoot WH; Ensink NG; Daha MR; Fleuren GJ
    Lab Invest; 1996 Jun; 74(6):1039-49. PubMed ID: 8667608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization against tumor cell surface complement-regulatory proteins.
    Durrant LG; Spendlove I
    Curr Opin Investig Drugs; 2001 Jul; 2(7):959-66. PubMed ID: 11757799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.
    Goslings WR; Blom DJ; de Waard-Siebinga I; van Beelen E; Claas FH; Jager MJ; Gorter A
    Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1884-91. PubMed ID: 8759358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma.
    Shimo K; Mizuno M; Nasu J; Hiraoka S; Makidono C; Okazaki H; Yamamoto K; Okada H; Fujita T; Shiratori Y
    J Gastroenterol Hepatol; 2004 Jun; 19(6):643-7. PubMed ID: 15151618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
    Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
    Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.
    Ziller F; Macor P; Bulla R; Sblattero D; Marzari R; Tedesco F
    Eur J Immunol; 2005 Jul; 35(7):2175-83. PubMed ID: 15971270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones.
    Chen S; Caragine T; Cheung NK; Tomlinson S
    Am J Pathol; 2000 Mar; 156(3):1085-91. PubMed ID: 10702424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research progression on complement regulatory proteins CD46, CD55, and CD59 in tumor immunotherapy].
    Qin C; Cai XY
    Ai Zheng; 2006 Nov; 25(11):1450-3. PubMed ID: 17094920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The complement regulatory proteins CD55 (decay accelerating factor) and CD59 are expressed on the inner acrosomal membrane of human spermatozoa as well as CD46 (membrane cofactor protein).
    Cummerson JA; Flanagan BF; Spiller DG; Johnson PM
    Immunology; 2006 Jul; 118(3):333-42. PubMed ID: 16827894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement regulatory proteins are expressed at low levels in embryonic human, wild type and transgenic porcine neural tissue.
    Harrower TP; Richards A; Cruz G; Copeman L; Dunnett SB; Barker RA
    Xenotransplantation; 2004 Jan; 11(1):60-71. PubMed ID: 14962294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59.
    Clayton A; Harris CL; Court J; Mason MD; Morgan BP
    Eur J Immunol; 2003 Feb; 33(2):522-31. PubMed ID: 12645951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours.
    Schmitt CA; Schwaeble W; Wittig BM; Meyer zum Büschenfelde KH; Dippold WG
    Eur J Cancer; 1999 Jan; 35(1):117-24. PubMed ID: 10211099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies.
    Gelderman KA; Blok VT; Fleuren GJ; Gorter A
    Lab Invest; 2002 Apr; 82(4):483-93. PubMed ID: 11950905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.
    Mäenpää A; Junnikkala S; Hakulinen J; Timonen T; Meri S
    Am J Pathol; 1996 Apr; 148(4):1139-52. PubMed ID: 8644856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line.
    Harris CL; Morgan BP
    Immunology; 1995 Oct; 86(2):311-8. PubMed ID: 7490134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
    Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
    J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.
    Montefiori DC; Cornell RJ; Zhou JY; Zhou JT; Hirsch VM; Johnson PR
    Virology; 1994 Nov; 205(1):82-92. PubMed ID: 7526538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cells.
    Spiller OB; Morgan BP; Tufaro F; Devine DV
    Eur J Immunol; 1996 Jul; 26(7):1532-8. PubMed ID: 8766557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
    Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
    Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.